Linkedin Twitter

WG4. Economic Exploitation

Activities

As mentioned before, Europe is losing leadership and competitiveness in NRF2-related pharmacology since products initially developed in Europe are being exploited in third countries. In this context, this WG will design the strategy to retain innovation and facilitate the transfer of knowledge to European industry by building bridges between academia and industry, and provide training and advice in knowledge/technology transfer and entrepreneurship to the next-generation researchers.

Task

  • Identification and active diffusion of BenBedPhar capabilities.
  • Identification and attraction of additional SMEs to the Action.
  • Elaboration of procedures, list of lead compounds, drug delivery systems, blood-based biomarkers for clinical implementation, or other technologic outcomes
  • Reinforce the BenBedPhar-industry cooperation by organizing 3 industry showcase events.

Members

Albena Dinkova-Kostova

  • School of Medicine
  • United Kingdom (UK)

Anders Bach

  • Professor, University of Copenhagen
  • Denmark
  • Website

Anton Terasmaa

  • National Institute of Chemical Physics and Biophysics
  • Estonia (EE)

Bilge Debelec Butuner

  • Ege University
  • Turkey (TR)
  • Website

Bruno Ramos-Molina

  • Biomedical Research Institute of Murcia (IMIB-Arrixaca)
  • Spain (ES)

Camillo Rosano

  • IRCCS AOU San Martino - IST National Institute for Cancer Research
  • Italy (IT)

Elena Poverenov

  • Agricultural Research Organization, the Volcani Center
  • Israel (IL)

Eugenia Carvalho

  • Center for Neuroscience and Cell Biology
  • Portugal (PT)

Gerasimos Sykiotis

  • Lausanne University Hospital
  • Switzerland (CH)

Gina Manda

  • Victor Babes National Institute of Pathology
  • Romania (RO)
  • Website

Ioannis P. Trougakos

  • National & Kapodistrian University of Athens
  • Greece (EL)

Isabel Lastres-Becker

  • Universidad Autónoma de Madrid
  • Spain (ES)

Joana Loureiro

  • Faculty of Engineering| University of Porto
  • Portugal (PT)

Juan Antonio Moreno

  • IMIBIC| Cordoba University
  • Spain (ES)
  • Website

Lidija Milkovic

  • Rudjer Boskovic Institute
  • Croatia (HR)
  • Website

Marco Peretto

  • Rafifarm SRL
  • Romania (RO)
  • Website

Maria Carmo Pereira

  • Faculdade de Engenharia da Universidade do Porto
  • Portugal (PT)

Maria Teresa Cruz

  • Center for Neuroscience and Cell Biology
  • Portugal (PT)

Marisa Andreia Carvalho de Freitas

  • Researcher at REQUIMTE/Faculty of Pharmacy of University of Porto
  • Portugal (PT)

Michel-Edwar Mickael

  • philopater Macavious Enskild firma (PM)
  • Egypt (EG)
  • Website

Murat Yılmaz

  • Assistant Professor Doctor/ Osmaniye Korkut Ata University
  • Turkey
  • Website

Sara Zakaria

  • Vem İlaç San. ve Tic. A.Ş.
  • Turkey (TR)
  • Website

Sharadha Dayalan Naidu

  • Website

Srdjan Bjedov

  • Faculty of Sciences – University of Novi Sad
  • Serbia (RS)

Theo ZACHARIS

  • Innovation & Strategy Advisor. BioGLOT ventures. Greek Scientists Society.
  • Greece
  • Website

Ugne Jonavice

  • State Research Institute Centre for Innovative Medicine
  • Lithuania (LT)
  • Website

Vera Marisa Costa

  • Toxicology Lab| Faculty of Pharmacy UP
  • Portugal (PT)

Subscribe to our newsletter

COST

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

BenBedPhar CA20121

Action details

Grant Holder: Universidad Autónoma de Madrid
Start of Action: 19 October, 2021
End of Action: 18 October, 2025
CSO approval date: 25 May 2021
Action email: info@benbedphar.org

© 2022 BenBedPhar | Design by Tuinbit Group